Clinical Trial Update: Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of rucaparib combined with nivolumab in prostate and endometrial cancer was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Prostate Cancer

Drugs mentioned

• Rucaparib (rucaparib)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Chicago | Conditions: Prostate Cancer, Endometrial Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-02-12